Cargando…

Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study

BACKGROUND: Spiromax® is a novel dry-powder inhaler containing formulations of budesonide plus formoterol (BF). The device is intended to provide dose equivalence with enhanced user-friendliness compared to BF Turbuhaler® in asthma and chronic obstructive pulmonary disease (COPD). The present study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azouz, Wahida, Chetcuti, Philip, Hosker, Harold, Saralaya, Dinesh, Chrystyn, Henry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450517/ https://www.ncbi.nlm.nih.gov/pubmed/25927483 http://dx.doi.org/10.1186/s12890-015-0043-x

Ejemplares similares

Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD
por: Giner, Jordi, et al.
Publicado: (2020)

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
por: Price, David B., et al.
Publicado: (2018)

Comparison of correct technique and preference for Spiromax®, Easyhaler® and Turbuhaler®: a single-site, single-visit, crossover study in inhaler-naïve adult volunteers
por: Rönmark, Per, et al.
Publicado: (2018)

Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler)
por: Sandler, Niklas, et al.
Publicado: (2016)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions
por: Canonica, Giorgio Walter, et al.
Publicado: (2015)

A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma
por: Virchow, J. Christian, et al.
Publicado: (2016)

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax(®) compared with Turbuhaler(®) in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain
por: Darbà, Josep, et al.
Publicado: (2017)

A budget impact analysis of Spiromax(®) compared with Turbuhaler(®) for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions
por: Darbà, Josep, et al.
Publicado: (2016)

Skills in Handling Turbuhaler, Diskus, and Pressurized Metered-Dose Inhaler in Korean Asthmatic Patients
por: Lee, Sang Min, et al.
Publicado: (2011)

Utility and effectiveness of Symbicort® Turbuhaler® (oral inhalation containing budesonide and formoterol) in a patient with severe asthma after permanent tracheostomy
por: Maeda, Kohhei, et al.
Publicado: (2018)

A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices
por: van der Palen, Job, et al.
Publicado: (2016)

A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices
por: van der Palen, Job, et al.
Publicado: (2017)

Investigating the Accuracy of the Digihaler, a New Electronic Multidose Dry-Powder Inhaler, in Measuring Inhalation Parameters
por: Chrystyn, Henry, et al.
Publicado: (2022)

Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use
por: Pilcher, Janine, et al.
Publicado: (2015)

Real-world evidence effect of budesonide+formoterol Spiromax on patients with asthma and chronic obstructive pulmonary disease in Sweden
por: Janson, Christer, et al.
Publicado: (2019)

Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control
por: Thomas, Mike, et al.
Publicado: (2009)

Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD
por: Kocks, Janwillem W. H., et al.
Publicado: (2018)

Skills in handling Turbuhaler, Diskus in the west of China
por: Wei, Wei, et al.
Publicado: (2023)

Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study
por: Pascual, Sergi, et al.
Publicado: (2015)

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
por: Voorham, Jaco, et al.
Publicado: (2018)

Choosing the right inhaler for your asthma or COPD patient
por: Usmani, Omar S
Publicado: (2019)

Device errors in asthma and COPD: systematic literature review and meta-analysis
por: Chrystyn, Henry, et al.
Publicado: (2017)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2019)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2018)

Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates
por: Schreiber, Jens, et al.
Publicado: (2020)

Acceptability and preference of three inhalation devices assessed by the Handling Questionnaire in asthma and COPD patients
por: Dal Negro, Roberto W., et al.
Publicado: (2016)

Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for Asthma and COPD Patients
por: Plaza, Vicente, et al.
Publicado: (2016)

Evaluation of inhaler technique among patients with asthma and COPD in Yemen
por: Al-Worafi, Yaser M.
Publicado: (2018)

The Diskus™: a review of its position among dry powder inhaler devices
por: Chrystyn, H
Publicado: (2007)

Impact of inhalation therapy on the incidence of carious lesions in patients with asthma and COPD
por: Bozejac, Branislava Velicki, et al.
Publicado: (2017)

Asthma and COPD Patients’ Perception of Appropriate Metered-Dose Inhaler Technique
por: Ramadan, Wijdan H., et al.
Publicado: (2020)

Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study
por: Zervas, Eleftherios, et al.
Publicado: (2016)

A review of the value of innovation in inhalers for COPD and asthma
por: Virchow, Johann Christian, et al.
Publicado: (2015)

Carbon footprint impact of the choice of inhalers for asthma and COPD
por: Janson, Christer, et al.
Publicado: (2020)

Control in asthma and COPD – correct inhaler technique is crucial
por: Irusen, E M
Publicado: (2019)

The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes
por: Bosnic-Anticevich, Sinthia, et al.
Publicado: (2016)

Advancing Digital Solutions to Overcome Longstanding Barriers in Asthma and COPD Management
por: Bosnic-Anticevich, Sinthia, et al.
Publicado: (2023)

Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients
por: Wang, S -T, et al.
Publicado: (2020)

Asthma control in patients receiving inhaled corticosteroid and long-acting beta(2)-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
por: Müller, Veronika, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_088lfmp3p2idg9v9dbngu68uh7